Verdesian Life Sciences

Our Approach

  • We provide highly tailored buyside support and advice
  • We leverage our extensive global network
  • We evaluate M&A growth potential

We employed these capabilities when we advised AEA Investors on its acquisition of Verdesian Life Sciences.


Chemicals & Ingredients
AEA Investors
Verdesian Life Sciences

Public or Private: Private

Client Position: Buyer

  • Company Profile
  • Transaction Background

AEA is a global private investment firm with over $15 billion assets under management, headquartered in New York.

The target, Verdesian Life Sciences, is a leading US agrochemicals platform that develops patented biological and nutritional fertilizer enhancers, seed treatment and inoculant technologies for high-value specialty crops, row crops, and turf and ornamental markets. Verdesian’s products promote sustainable agricultural practices by improving nutrient uptake and reducing the need for conventional chemicals.

  • Paine Schwartz Partners launched the competitive sale process of Verdesian in Q4 2020
  • Verdesian is a uniquely positioned business in the NAFTA bio/specialty fertilizer space
  • Opus assisted AEA on their evaluation of Verdesian as a platform for acquisition-led growth within this highly attractive sector